Bachem Holding AG, a technology-based biochemicals company, provides services to the pharmaceutical and biotechnology industries primarily in Switzerland, the United States, the United Kingdom, Germany, Austria, and Japan. More Details
No risks detected for BANB from our risk checks.
Excellent balance sheet with proven track record.
Share Price & News
How has Bachem Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BANB is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BANB's weekly volatility (4%) has been stable over the past year.
7 Day Return
CH Life Sciences
1 Year Return
CH Life Sciences
Return vs Industry: BANB exceeded the Swiss Life Sciences industry which returned 62% over the past year.
Return vs Market: BANB exceeded the Swiss Market which returned -0.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Bachem Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StDo Insiders Own Lots Of Shares In Bachem Holding AG (VTX:BANB)?
1 month ago | Simply Wall StBachem Holding (VTX:BANB) Has Rewarded Shareholders With An Exceptional 698% Total Return On Their Investment
1 month ago | Simply Wall StHere's Why Bachem Holding (VTX:BANB) Can Manage Its Debt Responsibly
Is Bachem Holding undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BANB (CHF381) is trading above our estimate of fair value (CHF73.55)
Significantly Below Fair Value: BANB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BANB is poor value based on its PE Ratio (79.9x) compared to the XE Life Sciences industry average (59.6x).
PE vs Market: BANB is poor value based on its PE Ratio (79.9x) compared to the Swiss market (24.5x).
Price to Earnings Growth Ratio
PEG Ratio: BANB is poor value based on its PEG Ratio (4.1x)
Price to Book Ratio
PB vs Industry: BANB is overvalued based on its PB Ratio (12.2x) compared to the XE Life Sciences industry average (5.3x).
How is Bachem Holding forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BANB's forecast earnings growth (19.5% per year) is above the savings rate (-0.3%).
Earnings vs Market: BANB's earnings (19.5% per year) are forecast to grow faster than the Swiss market (13% per year).
High Growth Earnings: BANB's earnings are forecast to grow, but not significantly.
Revenue vs Market: BANB's revenue (15.1% per year) is forecast to grow faster than the Swiss market (4.6% per year).
High Growth Revenue: BANB's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BANB's Return on Equity is forecast to be low in 3 years time (18.7%).
How has Bachem Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BANB has high quality earnings.
Growing Profit Margin: BANB's current net profit margins (18.7%) are higher than last year (16.5%).
Past Earnings Growth Analysis
Earnings Trend: BANB's earnings have grown by 13.4% per year over the past 5 years.
Accelerating Growth: BANB's earnings growth over the past year (31.5%) exceeds its 5-year average (13.4% per year).
Earnings vs Industry: BANB earnings growth over the past year (31.5%) underperformed the Life Sciences industry 31.5%.
Return on Equity
High ROE: BANB's Return on Equity (15.2%) is considered low.
How is Bachem Holding's financial position?
Financial Position Analysis
Short Term Liabilities: BANB's short term assets (CHF336.3M) exceed its short term liabilities (CHF130.3M).
Long Term Liabilities: BANB's short term assets (CHF336.3M) exceed its long term liabilities (CHF96.6M).
Debt to Equity History and Analysis
Debt Level: BANB's debt to equity ratio (26.1%) is considered satisfactory.
Reducing Debt: BANB's debt to equity ratio has increased from 8.6% to 26.1% over the past 5 years.
Debt Coverage: BANB's debt is well covered by operating cash flow (79.7%).
Interest Coverage: BANB's interest payments on its debt are well covered by EBIT (321.8x coverage).
What is Bachem Holding current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BANB's dividend (0.79%) isn’t notable compared to the bottom 25% of dividend payers in the Swiss market (1.62%).
High Dividend: BANB's dividend (0.79%) is low compared to the top 25% of dividend payers in the Swiss market (3.79%).
Stability and Growth of Payments
Stable Dividend: BANB is not paying a notable dividend for the Swiss market, therefore no need to check if payments are stable.
Growing Dividend: BANB is not paying a notable dividend for the Swiss market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: BANB is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BANB's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Meier (52 yo)
Mr. Thomas Meier has been Chief Executive Officer of Bachem Holding AG since 2020. Mr. Meier served as Chief Operations Officer at Bachem Group since January 1, 2019 until 2020. He joined Bachem AG in 1993...
|Chief Executive Officer||1yr||no data||0.016% |
|Chief Financial Officer||11.33yrs||no data||0.038% |
|Chief Operating Officer||0.50yr||no data||no data|
|Chief Technology Officer||6yrs||no data||0.017% |
|Chief Marketing Officer||3yrs||no data||0.013% |
|Director of Human Resources||no data||no data||no data|
|Head of Global Marketing||no data||no data||no data|
Experienced Management: BANB's management team is considered experienced (3 years average tenure).
|Honorary Chairman||no data||CHF211.00k||61.64% |
|Chairman of the Board||8.75yrs||CHF185.00k||0.054% |
|Director||1yr||no data||no data|
Experienced Board: BANB's board of directors are considered experienced (7.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bachem Holding AG's company bio, employee growth, exchange listings and data sources
- Name: Bachem Holding AG
- Ticker: BANB
- Exchange: SWX
- Founded: 1971
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF5.331b
- Shares outstanding: 13.99m
- Website: https://www.bachem.com
Number of Employees
- Bachem Holding AG
- Hauptstrasse 144
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BFEH.F||OTCPK (Pink Sheets LLC)||Yes||Class B Registered Shares||US||USD||Jun 1998|
|BANB||SWX (SIX Swiss Exchange)||Yes||Class B Registered Shares||CH||CHF||Jun 1998|
|BHM||DB (Deutsche Boerse AG)||Yes||Class B Registered Shares||DE||EUR||Jun 1998|
|0QND||LSE (London Stock Exchange)||Yes||Class B Registered Shares||GB||CHF||Jun 1998|
Bachem Holding AG, a technology-based biochemicals company, provides services to the pharmaceutical and biotechnology industries primarily in Switzerland, the United States, the United Kingdom, Germany, Au...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/16 18:10|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.